Agile Therapeutics Return on Tangible Equity 2013-2023 | AGRX
Current and historical return on tangible equity values for Agile Therapeutics (AGRX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Agile Therapeutics Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2023-12-31 |
$-0.01B |
$-0.02B |
114.29% |
| 2023-09-30 |
$-0.01B |
$-0.01B |
143.59% |
| 2023-06-30 |
$-0.02B |
$-0.01B |
361.90% |
| 2023-03-31 |
$-0.02B |
$-0.01B |
1333.33% |
| 2022-12-31 |
$-0.03B |
$-0.01B |
-1666.67% |
| 2022-09-30 |
$-0.04B |
$0.01B |
-1025.00% |
| 2022-06-30 |
$-0.05B |
$0.00B |
-990.48% |
| 2022-03-31 |
$-0.07B |
$0.00B |
-604.65% |
| 2021-12-31 |
$-0.07B |
$0.00B |
-384.00% |
| 2021-09-30 |
$-0.07B |
$0.01B |
-233.33% |
| 2021-06-30 |
$-0.07B |
$0.03B |
-157.71% |
| 2021-03-31 |
$-0.06B |
$0.04B |
-107.36% |
| 2020-12-31 |
$-0.05B |
$0.05B |
-73.87% |
| 2020-09-30 |
$-0.04B |
$0.07B |
-57.75% |
| 2020-06-30 |
$-0.03B |
$0.08B |
-46.40% |
| 2020-03-31 |
$-0.02B |
$0.09B |
-43.75% |
| 2019-12-31 |
$-0.02B |
$0.05B |
-57.14% |
| 2019-09-30 |
$-0.02B |
$0.03B |
-64.00% |
| 2019-06-30 |
$-0.02B |
$0.02B |
-70.33% |
| 2019-03-31 |
$-0.02B |
$0.03B |
-76.60% |
| 2018-12-31 |
$-0.02B |
$0.02B |
-80.00% |
| 2018-09-30 |
$-0.02B |
$0.02B |
-75.86% |
| 2018-06-30 |
$-0.03B |
$0.03B |
-74.07% |
| 2018-03-31 |
$-0.03B |
$0.03B |
-78.26% |
| 2017-12-31 |
$-0.03B |
$0.04B |
-78.32% |
| 2017-09-30 |
$-0.03B |
$0.04B |
-72.48% |
| 2017-06-30 |
$-0.03B |
$0.03B |
-72.73% |
| 2017-03-31 |
$-0.03B |
$0.04B |
-64.80% |
| 2016-12-31 |
$-0.03B |
$0.04B |
-54.90% |
| 2016-09-30 |
$-0.03B |
$0.05B |
-56.25% |
| 2016-06-30 |
$-0.03B |
$0.05B |
-62.92% |
| 2016-03-31 |
$-0.03B |
$0.06B |
-67.88% |
| 2015-12-31 |
$-0.03B |
$0.03B |
-78.43% |
| 2015-09-30 |
$-0.03B |
$0.03B |
-80.50% |
| 2015-06-30 |
$-0.03B |
$0.04B |
-69.05% |
| 2015-03-31 |
$-0.03B |
$0.05B |
-57.14% |
| 2014-12-31 |
$-0.02B |
$0.04B |
-50.79% |
| 2014-06-30 |
$-0.01B |
$0.05B |
-66.67% |
| 2014-03-31 |
$-0.01B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.003B |
$0.020B |
|
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|
